hVIVO plc
("hVIVO", the "Company" or
the "Group")
hVIVO to present at Jefferies
London Healthcare Conference
hVIVO plc (AIM: HVO), a fast-growing
specialist contract research organisation (CRO) and world leader in
testing infectious and respiratory disease products using human
challenge clinical trials, announces that Yamin 'Mo' Khan, Chief
Executive Officer, will be presenting in-person at the Jefferies
Healthcare Conference in London on 19 November 2024 at 12:00pm GMT.
Alongside the presentation, the Company will also be available for
one-to-one meetings.
The Jefferies Conference is the
largest healthcare-dedicated conference in Europe. The conference
hosts over 650 healthcare companies, 3,000 attendees, and nearly
8,000 investor and business-to-business meetings. The conference
will feature leading public and private companies from the
pharmaceuticals, biotechnology, medical technology, and healthcare
services sectors from the Americas, Europe, Middle East, Africa,
Asia, and Australia.
For
further information please contact:
|
hVIVO plc
|
+44 (0) 20
7756 1300
|
|
Yamin 'Mo' Khan, Chief Executive Officer
Stephen Pinkerton, Chief Financial
Officer
|
|
|
|
|
|
Cavendish Capital Markets Limited (Nominated Adviser and Joint
Broker)
|
+44 (0) 20
7220 0500
|
|
Geoff Nash, Camilla Hume, Harriet
Ward
Nigel Birks - Life Science
Specialist Sales
Louise Talbot - Sales
|
|
|
|
|
|
Peel Hunt LLP (Joint Broker)
|
+44 (0)20
7418 8900
|
|
James Steel, Dr Christopher Golden
|
|
|
|
|
|
Davy (Euronext Growth Adviser and Joint
Broker)
|
+353 (0) 1
679 6363
|
|
Anthony Farrell, Niall
Gilchrist
|
|
|
|
|
|
Walbrook PR (Financial PR & IR)
Paul McManus / Phillip Marriage
/
Louis Ashe-Jepson
|
+44 (0) 20
7933 8780 or hvivo@walbrookpr.com
+44 (0)
7980 541 893 / +44 (0) 7867 984 082 /
+44 (0) 7747 515 393
|
|
|
|
|
|
Notes to
Editors
hVIVO plc
(ticker: HVO) is a fast-growing specialist contract research
organisation (CRO) and the world leader in testing infectious and
respiratory disease vaccines and therapeutics using human challenge
clinical trials. The Group provides end-to-end early clinical
development services to its large, established and growing repeat
client base, which includes four of the top 10 largest global
biopharma companies.
The Group's fast-growing services business
includes a unique portfolio of 11 human challenge models, with a
number of new models under development, to test a broad range of
infectious and respiratory disease products. The Group has world
class challenge agent manufacturing capabilities, specialist drug
development and clinical consultancy services via its Venn Life
Sciences brand, and a lab offering via its hLAB brand, which includes
virology, immunology biomarker and molecular testing. The Group
also offers additional clinical field trial services such as
patient recruitment and clinical trial site services.
hVIVO runs challenge trials in London -
its new state-of-the-art facilities in Canary Wharf opened in 2024
and is the world's largest commercial human challenge trial unit,
with highly specialised on-site virology and immunology
laboratories, and an outpatient unit. To recruit volunteers /
patients for its studies, the Group leverages its unique clinical
trial recruitment capability via its FluCamp volunteer screening
facilities in London and Manchester.
